In The News Posted August 6, 2022 Share Posted August 6, 2022 SYDNEY, 6 août 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA ; ASX: KZA), une société de développement de médicaments axée sur l'oncologie, a le plaisir d'annoncer la présentation de nouvelles données prometteuses issues d'un essai clinique de phase I en cours sur le...View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now